MDMA

What is MDMA? 

MDMA, also known as 3,4-methylenedioxymethamphetamine, is a psychoactive drug that belongs to the amphetamine class. It is commonly referred to as ecstasy or molly. MDMA was first synthesized in the early 1900s, but its recreational use gained popularity in the 1980s and 1990s as a party drug and for its empathogenic effects.

MDMA produces a combination of stimulant and hallucinogenic effects. It primarily affects the neurotransmitters serotonin, dopamine, and norepinephrine in the brain. The drug increases the release and inhibits the reuptake of these neurotransmitters, resulting in increased feelings of euphoria, empathy, emotional openness, and heightened sensory perception.

It's important to note that while MDMA can produce positive subjective effects, it also carries potential risks. It can cause dehydration, overheating, and cardiovascular problems, especially when used in high doses or in combination with other substances.  Research studies on MDMA have explored its potential therapeutic uses, particularly in the treatment of post-traumatic stress disorder (PTSD). These studies have shown promising results in clinical trials, but it's important to note that further research is still ongoing, and MDMA-assisted therapy is not yet approved for widespread use.  

Here are some key research studies and developments related to MDMA:

1. MAPS Clinical Trials: The Multidisciplinary Association for Psychedelic Studies (MAPS) has been at the forefront of MDMA research. They have conducted Phase 2 clinical trials and are currently conducting Phase 3 trials to assess the safety and efficacy of MDMA-assisted therapy for PTSD. The results so far have been encouraging, showing significant reductions in PTSD symptoms in participants.
2. FDA Breakthrough Therapy Designation: In 2017, the U.S. Food and Drug Administration (FDA) granted MDMA-assisted therapy for PTSD the Breakthrough Therapy designation, recognizing its potential as a promising treatment. This designation facilitates an expedited development and review process.
3. Expanded Access Program: The FDA has also approved an Expanded Access Program, allowing certain individuals with treatment-resistant PTSD to receive MDMA-assisted therapy under carefully controlled conditions before the drug is officially approved.
4. International Research: MDMA research is not limited to the United States. Other countries, such as Canada, Switzerland, Israel, and the United Kingdom, have also conducted studies exploring the therapeutic potential of MDMA for various mental health conditions.

These studies suggest that MDMA, when combined with psychotherapy, may help individuals with PTSD process traumatic memories, reduce anxiety, and improve emotional well-being. However, it's important to note that these studies involve controlled settings, trained therapists, and specific protocols to ensure safety and maximize therapeutic benefits.

It's crucial to distinguish between MDMA-assisted therapy conducted in clinical trials and recreational or uncontrolled use of MDMA, which can carry significant risks and potential harm. MDMA obtained illegally or used without proper medical supervision can have adverse effects on physical and mental health. If you're interested in learning more about the current status of MDMA research or considering MDMA-assisted therapy, it's best to consult with medical professionals or organizations conducting clinical trials for the most accurate and up-to-date information.

MDMA & Other Research 

• Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment. https://www.tandfonline.com/doi/full/10.1080/09687637.2021.1897331 
• 10 Calls to Action: Toward an LGBTQ-Affirmative Psychedelic Therapy https://chacruna.net/10-calls-to-action-toward-an-lgbtq-affirmative-psychedelic-therapy/
• MDMA-AT provided to patients with severe or extreme chronic PTSD is cost-saving from a payer’s perspective while delivering substantial clinical benefit. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0263252
• FDA designated MDMA-assisted psychotherapy for PTSD as a "breakthrough therapy," meaning the administration believes it may prove more beneficial than current treatments. https://www.military.com/benefits/veterans-health-care/ptsd/mdma-therapy-gaining-popularity-ptsd-treatment.html